Kornimate/medical-research-clean huggingface dataset:
new educational tool for fm

Conditions: Fibromyalgia

Summary: this study aims at analyzing the usefulness of a new educational tool developed by pain revolution, a compendium of 9 fact sheets along with a related quiz in patients from the hospital vall d'hebron of barcelona suffering from fibromyalgia, compared to a non-education group. the present study also aims at comparing the usefulness of the new tool based on pne in two different formats: read and explained.

main objective a compendium of 9 fact sheets along with a related quiz have been developed in order to provide overall population current pain-science knowledge. the present study aims at analyzing the usefulness of this new tool based on pain neuroscience education (pne) in patients from the hospital vall d'hebron of barcelona suffering from fibromyalgia, compared to a non-education group. secondary objective due to the extended content of the fact sheets, these can be delivered to the patient as a reading material or can be used as a support material in a educational presentation. therefore, this study also aims at comparing the usefulness of the new tool based on pne in two different formats: read autonomously by the patient and explained by a pain-science expert to the patient. this is a tree-arm rct: tau group and intervention group with 2 different groups as follows: the intervention program is divided in two groups. both groups will be provided with the pne fact sheets but in different format (read and explained) and will be given one week to comprehend the content before to assess their knowledge. therefore, intervention groups will be informed that a quiz about the fact sheets will be delivered to each one in order to asses their acquired knowledge. there are 9 fact sheets overall. and each fact sheet incorporates two pages relating to one main concept. the first of two pages introduces the concept, and the second one quotes important ideas that emerge from the main concept. the 9 main concepts and consequent ideas presented in the fact sheets are based on current scientific research in pain science and have been selected and structured specifically for pne education for chronic pain patients. the fact sheets have been fully developed and designed by pain revolution, a pain educator network founded by professor lorimer moseley, group leader in body in mind research group from university of south australia.

Eligibility criteria:
inclusion criteria: * adults from 18 to 75 years-old. * 1990 american college of rheumatology (acr) classification criteria + the 2011 modified acr diagnostic criteria for fibromyalgia * able to understand spanish and accept to participate in the study. exclusion criteria: * participating in concurrent or past rcts (previous year). * comorbidity with severe mental disorders (i.e. psychosis) or neurodegenerative diseases (i.e. alzheimer) that that would limit the ability of the patient to participate in the rct.

Keywords: fibromyalgia pain neuroscience education pain fact sheets
aflibercept in recurrent or persistent cnv

Conditions: Age Related Macular Degeneration; Intravitreal Injections; Diabetic Macular Edema

Summary: age-related macular degeneration (amd) and diabetic retinopathy are among the most common disorders causing visual disability in elderly people. amd leads to dysfunction and loss of photoreceptors in the central retina. neovascular amd (namd) affects visual function early in the disease process. the purpose of the study is to evaluate the effect of switching from ranibizumab therapy to the current routine therapy using aflibercept in eyes with treatment naive, recurrent or persistent namd, treatment naive diabetic retinopathy and pretreated diabetic retinopathy. 20 patients with recurrent or persistent namd, previously treated with intravitreal ranibizumab for up to one year will be included in this trial. patients will be examined in monthly intervals over 12 months follow-up. examinations carried out will include: best-corrected visual acuity (bcva) using etdrs charts at 4m distance, reading performance (rp), standard ophthalmic examinations (soe incl. funduscopy and applanation tonometry), optical coherence tomography (oct), autofluorescence fundus image (af) \& red-free autofluorescence fundus image (rf), color fundus photography (cfp), fluorescein angiography and indocyaningreen angiography (fla/icg), microperimetry (mp), as well as non-invasive oct based optical angiography (angiovue).


Eligibility criteria:
inclusion criteria: adults ≥ 50 years * patients who have been treated with ranibizumab due to wet age-related macular degeneration for up to one year * bcva \>= 20/400 in the study eye using etdrs * willingness and ability to comply with regular visits * signed informed consent exclusion criteria: * any surgical treatment of the eye within 3 months prior to baseline in the study eye * history of uncontrolled glaucoma in the study eye (defined as intraocular pressure ≥ 25 mmhg despite treatment with anti-glaucoma mediation) * aphakia or absence of the posterior capsule (excluding yag-capsulotomy) in the study eye * retinal pigment epithelial tear involving the macula in the study eye
study on the safety and effectiveness of remimazolam tosilate for injection for short-term elective surgery in adults

Conditions: Hypotension During Surgery

Summary: research objective: to explore the safety and dose exploration of remimazolam tosilate for injection for induction and maintenance of general anesthesia in elective short-term surgery in adults. main research indicators:(1)success rate of sedation during induction and maintenance of general anesthesia with remazolam tosylate;(2)the incidence and severity of hypotension in the induction and maintenance phases study design: multi-center, randomized, double-blind clinical study. subject population: patients undergoing elective short-term surgery. research data collection period: the subject signs the consent form until discharge or death in the hospital or withdrawal from the research. number of research centers/sample size: it is planned to enroll 600 patients from 11 hospitals. research process: the researchers will include patients who meet the enrollment criteria and agree to participate in the investigation of the support laryngoscope surgery and minor head and neck surgery patients from the elective surgery patients.

the data collected in this study is recorded by the researcher in the ecrf, including: 1. data to be collected during the screening period and before the operation: the basic characteristics of the patient and demographic data; 2. data to be recorded during and/or postoperatively: main research indicators, secondary indicators and other indicators.

Eligibility criteria:
inclusion criteria: 1. asa ⅰ-ⅲ grade; 2. age 18-65 years old; 3. gender is not limited; 4. planned elective support laryngoscope surgery (glottic polypectomy under support laryngoscope, epiglottic cyst excision under support laryngoscope, benign laryngeal under support laryngoscope lesion resection), endoscopic septoplasty, endoscopic tympanoplasty, endoscopic middle ear tube insertion, nasopharyngoplasty, head and neck benign mass resection for general anesthesia intubation patients; 5. operation time no more than 90min. exclusion criteria: - emergency surgery; 1. abnormal renal function (urea nitrogen ≥1.5×uln, blood creatinine greater than the upper limit of normal); 2. abnormal liver function; 3. hypovolemia, shock or coma; 4. suffering from mental illness and long-term use of psychotropic drugs; 5. cognition dysfunction; 6. those who are allergic to or contraindicated to benzodiazepines and their drug components; pregnant or lactating female patients; 7. have a history of drug dependence; 8. have used other sedatives in the past week; 9. have been a subject within the past 3 months participated in drug clinical trials
tace+rfa versus tace alone for intermediate-stage hepatocellular carcinoma

Conditions: Hepatocellular Carcinoma; Chemoembolization, Therapeutic; Ablation Techniques, RFA

Summary: the current standard treatment for intermediate-stage hcc (bclc stage b) is transcatheter arterial chemoembolization (tace) alone.the combination of tace with rfa has also reported to be an effective treatment for hcc. some prospective studies have shown tace combined rfa to have better efficacy than any of them alone for early stage hcc (single tuomor ≤5 cm). however, to the investigators' knowledge, there have not been any prospective studies to assess whether tace combined sequentially with rfa is more effective than tace alone for the treatment of intermediate-stage hcc. the investigators hypothesized that the combination of tace and rfa might result in better patient survival than tace alone. thus, the purpose of this study was to prospectively compare the effects of sequential tace-rfa with tace alone for the treatment of intermediate-stage hcc. intermediate-stage hcc in this study was defined as 2-3 intrahepatic lessions, largest tumor size 3-7 cm or 4-10 intrahepatic lessions, largest tumor size ≤7 cm; ecog-ps 0;child-pugh a or b;no tumor thrombus or extrahepatic metastases.


Eligibility criteria:
inclusion criteria: * multiple hcc (2-3 lesions), largest lesion 3-7 cm in diameter, or multiple hcc (4-10 lesions), each ≤ 7 cm in diameter * no vascular invasion or etrahepatic metastases * eastern cooperative oncology group performance status 0-1 * child-pugh stage a or b * treatment naive exclusion criteria: * a platelet counts of \<40×109/l，prothrombin time activity \<40%; * albumin \>2.8 g/dl, total bilirubin \<51.3 umol/l; alanine aminotransferase (alt) and aspartate transaminase（ast）\<5 times of upper limit * no evaluale target lesions * uncontrolled or refractory ascites, ongoing variceal bleeding or encephalopathy * severe heart, brain or kidney diseases * previous or concurrent cancer that is distinct in primary site or histology from hcc * pregnant women or lactating women * be allergic to adriamycin, lobaplatin, mitomycin and iodized oil

Keywords: hepatocellular carcinoma,tace,chemoembolization, rfa,intermediate-stage
association of bone quality and quantity with vascular calcification

Conditions: Vascular Calcification; Atherosclerosis; Bone Density

Summary: the purpose of this study is to determine if there is a link between calcium build up in the veins or arteries (including the veins/arteries of the heart) and deterioration of the bone. this will help understand if there is a connection between heart disease and bone disease.


Eligibility criteria:
inclusion criteria: * male or female * 30 years of age or older * must already be scheduled to have a ct examination of the arteries of the heart exclusion criteria: * diagnosed with bone cancer * previous diagnosis of cancer that's spread to the bone * history of cancer that involves bone marrow * any bone disease other than osteoporosis * any disease which leads to serious osteoporosis or vascular calcification such as: * kidney disease * thyroid and adrenal disease * anorexia nervosa * secondary osteoporosis

Keywords: calcification osteoporosis
anorexia nervosa and its effects on brain function, body metabolism and their interaction in adolescents

Conditions: Anorexia Nervosa

Summary: the aim of the research project is to investigate the neurological, physiological and behavioral underpinnings associated with the development of anorexia nervosa in adolescents. the goal of the project is to enable new ways to both predict the course of the disease and to influence this process.

the aim of the project is to enable new ways to both predict and influence the course of anorexia nervosa. this is a three-year follow-up study in which we investigate the neurological and physiological factors underpinnings of anorexia nervosa with structural and functional magnetic resonance imaging (fmri). in addition to this, a variety of methods is used, such as physiological measurements and questionnaire data, as well as investigation of intestinal microbiota associated with anorexia nervosa. altogether 100 girls aged 13-17 will be recruited for the study: 50 patients with anorexia nervosa and 50 healthy controls. the participants are monitored annually and the fmri scan is repeated at the last visit. additionally, 40 participants (20 patients and 20 healthy controls) will participate in a cardiac sub-study. in this, the participants will also have an mri scan and ultrasound examination of the heart.

Eligibility criteria:
inclusion criteria for anorexia nervosa patients: * female sex * age 13-17 years * body mass index \< 17.5 kg/m2 * currently fulfilling modified diagnostic and statistical manual of mental disorders (dsm-iv) diagnosis criteria for anorexia nervosa with or without amenorrhea * anorexia nervosa diagnosed within 2 yers inclusion criteria for healthy controls: * female sex * age 13-17 years * body mass index 18,5-25 kg/m2 * no lifetime history of obesity (body mass index ≥ 30) or eating disorders exclusion criteria: * any chronic illness or medication that could affect glucose metabolism or neurotransmission * any other current mental disorder (excluding anorexia nervosa for the patient participants) * severe previous mental disorder (excluding anorexia nervosa for the patient participants) * smoking of tobacco, snuffing, or use of narcotics * abusive use of alcohol

Keywords: anorexia nervosa metabolism functional imaging eating disorders
are opioids needed after acl reconstruction

Conditions: Anterior Cruciate Ligament Rupture

Summary: as the public health sector continues to confront the opioid epidemic, orthopaedic surgeons must revisit pain management protocols to reduce unnecessary opioid prescriptions. the long-term goal is to reduce opioid use and residual opioids in circulation.

as the public health sector continues to confront the opioid epidemic, orthopaedic surgeons must revisit pain management protocols to reduce unnecessary opioid prescriptions. the long-term goal is to reduce opioid use and residual opioids in circulation. the purposes are to 1) conduct a double-blinded randomized controlled trial to determine the effectiveness of opioid versus non-opioid medications on post-surgical pain, and 2) examine predictors of opioid usage in individuals following anterior cruciate ligament (acl) reconstruction. patients will use an innovative smartphone application to track pain and medication usage. additionally, patients will complete quality of life and pain catastrophizing questionnaires, as well as undergo pain threshold testing, to be used in a model to determine predictors of greater post-surgical opioid use. this study will provide information on non-opioid alternatives and specific predictors of post-surgical opioid use that can be used to develop prescribing protocols. these findings will help orthopaedic surgeons make informed decisions when tailoring individualized prescriptions for patients following acl reconstruction. importantly, findings will be readily translatable into research to reduce opioid use in other orthopaedic surgical cohorts as well. our ultimate goal is to lessen the burden of the opioid epidemic on not only our orthopaedic patients, but also society, by minimizing the number of opioids left in circulation.

Eligibility criteria:
inclusion criteria: * males and females * aged 14-40 years * scheduled for primary (anterior cruciate ligament) acl reconstruction using quadriceps tendon autograft. exclusion criteria: * revision and/or contralateral acl reconstruction procedures * allergies to local anesthetics * chronic pain medication use * weight \<50 kg, local infections * known coagulopathies, * liver dysfunction or renal failure

Keywords: opioids
synergy lens outcomes evaluation

Conditions: Presbyopia; Pseudophakia

Summary: this is a single visit study to evaluate the visual outcomes and patient satisfaction of patients who were bilaterally implanted with the tecnis synergy iol between june 1 and december 31, 2021 in 2 centers in usa


Eligibility criteria:
inclusion criteria: 1. age: 18 years and older. 2. gender: males and females. 3. uneventful bilateral lens extraction 4. bilateral implantation of synergy iols (toric and non-toric) by 5 anterior segment surgeons at center for sight (dws, wjl, jwk, wls, and jod) and 1 surgeon at carolina eyecare physicians (kds) through the months of june to december 2021. 5. willing and able to provide written informed consent for participation in the study. 6. willing and able to comply with scheduled visit and study examination procedures. 7. at least 3 months postoperative from second eye iol implantation. 8. postoperative best corrected visual acuity of 0.2 logmar (20/32 snellen) or better in both eyes. exclusion criteria: 1. established ocular pathology, including: glaucoma (except glaucoma suspects), uveitis, and clinically-significant retinal pathology affecting the macula (with visual acuity worse than 20/32) and/or any other ocular findings that may, in the opinion of the investigator, affect vision. 2. uncontrolled diabetes. 3. use of any systemic or topical drug known to interfere with visual performance. 4. any concurrent infectious/non-infectious conjunctivitis, keratitis or uveitis. 5. clinically significant corneal dystrophy. 6. irregular astigmatism. 7. history of chronic intraocular inflammation. 8. previous intraocular surgery. 9. previous keratoplasty 10. previous refractive surgery. 11. severe dry eye 12. pupil abnormalities 13. any clinically significant, serious or severe medical or psychiatric condition that may interfere with the interpretation of study results. 14. participation in (or current participation) any ophthalmic investigational drug or ophthalmic device trial within the previous 30 days prior to the start date of this trial. 15. best-corrected distance visual acuity worse than 20/32 in each eye. 16. inability to focus or fixate for prolonged periods of time (e.g., due to strabismus, nystagmus, etc.) 17. abnormal iris 18. patients who had a complication during cataract surgery, which could include ruptured zonules, torn capsule, or vitrectomy.
neurofilament light protein in peripheral blood used as a biomarker for neurotoxicity after isolated limb perfusion.

Conditions: Malignant Melanoma

Summary: a prospective feasibility trial initially including 10 patients to investigate if neurofilament light protein can be detected in peripheral blood in patients undergoing isolated limb perfusion with chemotherapeutic agents. this biomarker could act as predictive biomarker for neurotoxicity after isolated limb perfusion.

in isolated limb perfusion (ilp) neurotoxicity is a known side effect, this is in spite of the fact that a relatively mild hyperthermic temperature is used which should be well tolerated by the nerves and other normal tissues in the limbs. it seems probable that the neurotoxicity observed after ilp results from both a thermal enhancement of drug toxicity combined with a local effect of a high tourniquet pressure that is used to isolate the blood flow. prevention of regional and systemic toxicity is essential for improving the outcome after the procedure. it is known that both higher doses of melphalan, higher temperatures and longer perfusion time correlates to a higher toxicity. the wieberdink method is a grading system for the reaction of the normal tissues after ilp and the grading is used as a routine in ilp today. neurofilament light protein (nfl) is released into the cerebrospinal fluid (csf) during axonal damage and has been shown to be elevated in different forms of dementia. an nfl assay sensitive enough to measure nfl in blood was recently developed. its concentration reflects axonal injury in both central and peripheral nervous system disorders.the primary aim of this study is to investigate the possibility to measure neurofilament as a biomarker for peripheral nerve toxicity after isolated limb perfusion.

Eligibility criteria:
inclusion criteria: 1. patient scheduled for treatment with isolated limb perfusion 2. age over 18 years 3. signed informed consent exclusion criteria: * none

Keywords: toxicity biomarker neurofilament light protein in-transit metastasis hyperthermic isolated limb perfusion
the role of hmgb-1 in chronic stroke

Conditions: Cerebrovascular Accident; Cerebral Stroke; Stroke, Acute

Summary: the purpose of this study is to measure the presence of hmgb-1 and other proteins in the blood across five time points after stroke, and to determine if their presence correlates with rate of stroke recovery.

stroke, cerebrovascular accident, is the leading cause of brain injury and the leading cause of permanent disability. the acute pathophysiology of stroke depends on the innate immune response, which arises from mostly pro-inflammatory cascades. the chronic pathophysiology of stroke is less clear as the innate inflammatory response fades and matures into an adaptive immune response. hmgb-1 is a serum cytokine that has been found with persistent elevated levels for weeks to months after neurological insult in preclinical experiments, and may retard functional recovery. elucidation of the relationship between hmgb-1 levels and the rate of functional recovery after stroke could lead to a better understanding of the systemic inflammatory response and more targeted therapeutic interventions.

Eligibility criteria:
inclusion criteria: * patients admitted to the stroke service at northshore and lij medical centers * patients 18 years of age or older exclusion criteria: * patients \< 18 years of age

Keywords: stroke cerebrovascular accident hmgb-1 cytokines functional recovery inflammation immune response
monthly itraconazole versus classic homeopathy for treatment of recurrent vulvovaginal candidiasis (rvvc)

Conditions: Vulvovaginal Candidiasis

Summary: a prospective study to evaluate the efficacy of classic homeopathic therapy compared to maintenance itraconazole therapy with and without additional exogenous lactobacillus for treatment of recurrent candida vaginitis.

objective: antimycotics effectively treat sporadic and recurrent vulvovaginal candidiasis (rvvc). classic homeopathy (ch) is also used to treat this condition. we compared the efficacy of ch and itraconazole in reducing the frequency of rvvc episodes. design: single-centre, prospective, randomized. sample: one-hundred-and-fifty patients with a history of rvvc and an acute episode of vvc. methods: women were randomised into 3 groups: itraconazole with lactobacilli (group 1), itraconazole without lactobacilli (group 2) and ch (group 3). itraconazole treatment of acute infection was followed by a 6-months maintenance regimen with monthly single-day itraconazole (200 mg bid). thereafter, patients were followed without treatment for 6 months. women in group 1 were given additional vaginal lactobacilli for six days per month. ch treatment was performed for 12 months.

Eligibility criteria:
inclusion criteria: * patients over 18 years, premenopausal * negative pregnancy test * signed informed consent * at least 4 episodes of candidiasis within the last year * candida detectable by culture * negative hepatitis- and hiv-serology * no allergy to itraconazole exclusion criteria: * under 18 years

Keywords: recurrent vulvovaginal candidiasis itraconazole classic homeopathy